iX Biopharma

Broker's Digest: Samudera, Raffles Medical, Multi-Chem, iX Biopharma, Hong Leong Asia - THE EDGE SINGAPORE

Broker's Calls

Broker's Digest: Samudera, Raffles Medical, Multi-Chem, iX Biopharma, Hong Leong Asia

Samudera Shipping Line
Price target:
UOB Kay Hian "unrated"

Gainer from favourable freight rates

PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement - THE EDGE SINGAPORE

Broker's Calls

PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement

iX Biopharma remains a “buy” for PhillipCapital analyst Tay Wee Kuang, with an unchanged target price of 44.5 cents, as the specialty pharmaceutical company announced that it has entered into a str

iX Biopharma enters agreement with Chinese pharmaceutical distributor to tap China market - THE EDGE SINGAPORE

Deals, joint ventures & alliances

iX Biopharma enters agreement with Chinese pharmaceutical distributor to tap China market

Specialty pharmaceutical company iX Biopharma has entered into a strategic cooperation framework agreement with China Resources Pharmaceutical Commercial Group Co (CRPCG) to collaborate o

973 Brokers' Digest - THE EDGE SINGAPORE

Broker's Calls

973 Brokers' Digest

ST Engineering
Price target:
RHB “buy” $4.25
CGS-CIMB “buy” $4.00

iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21 - THE EDGE SINGAPORE

Broker's Calls

iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21

PhillipCapital is maintaining its “buy” call on Ix Biopharma, but at a lower target price of 44.5 cents.

IX Biopharma appoints Eva Tan as CCO  - THE EDGE SINGAPORE

New appointments

IX Biopharma appoints Eva Tan as CCO

Speciality pharmaceutical company iX Biopharma has appointed Eva Tan as its new chief commercial officer. 

PhillipCapital eyes year-end STI at 3,200 - THE EDGE SINGAPORE

Positioning for the recovery

PhillipCapital eyes year-end STI at 3,200

Stock markets have remained volatile as countries take turns going into lockdowns to curb subsequent waves of the Covid-19 virus, creating near-term economic uncertainty.

iX Biopharma obtains approval and registration of male erectile dysfunction drug in Singapore - THE EDGE SINGAPORE

Company in the news

iX Biopharma obtains approval and registration of male erectile dysfunction drug in Singapore

iX Biopharma has obtained approval and registration by the Health Sciences Authority (HSA) for Silcap, a sildenafil drug that is used in the treatment of male erectile dysfunction on Oct 20.

Broker's Calls

Phillip Securities initiates 'buy' for iX Biopharma on prospect of turning profitable in FY21

Phillip Securities has initiated coverage on iX Biopharma with a “buy” recommendation and target price of 45.5 cents.

iX Biopharma secures Australia's GMP licence for its testing laboratory - THE EDGE SINGAPORE

Company in the news

iX Biopharma secures Australia's GMP licence for its testing laboratory

iX Biopharma’s wholly-owned subsidiary iX Syrinx has obtained the good manufacturing practice (GMP) licence issued by the Therapeutic Goods Administration (TGA) of Australia for its testing laborat

×